Application of osteopontin inhibitor in rheumatoid arthritis treatment

A technology of osteopontin and rheumatoid, applied in the direction of anti-inflammatory agents, bone diseases, non-central analgesics, etc., can solve problems such as unclear functional relationship, unclear pathogenesis, and obstacles to the diagnosis and treatment of rheumatoid arthritis

CN1827777AInactive Publication Date: 2006-09-06SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
0 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2006-09-06
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses the bone bridge protein. The invention also discloses the application of cytokine, acceptor and inhibiting agent in diagnosing and treating RP. The invention also provides the diagnosis agent case. The research expresses that the expression of OPN on film infiltration T cell has great relation with the local inflammation environment. The over expression of OPN on film infiltration T cell has relation with the high expression of film T cell OPN acceptor selective. The IL-10 in RP patient can stimulate T cell to heighten the OPN expression, and the IL-10 antibody can interdict the action.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of biological detection and diagnosis, in particular, the invention relates to a protein-osteopontin which plays an important role in the pathogenesis of rheumatoid arthritis. The invention also discloses the application of osteopontin and related cytokines, receptors and inhibitors in diagnosing or treating rheumatoid arthritis. The invention also provides corresponding diagnostic kits. Background technique

[0002] Although the etiology and pathogenesis of rheumatoid arthritis (RA) are still unclear, it has been recognized that T cell-mediated inflammation plays an important role in the process of rheumatoid synovial lesions. Type II collagen and heat shock proteins are autoantigens in the pathogenesis of rheumatoid arthritis (1-4), although the role of these autoantigens in disease pathology is not well understood. However, studies have clearly recognized that T lymphocytes, especially Th1 cells, are re...

Examples

Embodiment

[0063] method:

[0064] Patients and Experimental Materials

[0065] A total of 95 RA patients were collected in this study. All patients met the diagnostic criteria of the American College of Rheumatology. The sex ratio of RA patients was: 68 females and 27 males; the disease duration was 15±12 years. The patient's age was 54±19 years old. There were 32 complete paired samples, and each patient had peripheral blood, joint fluid and joint synovial tissue. Another group of 63 paired samples had synovial fluid and serum (without cells), and ELISA was used to analyze the concentrations of OPN and cytokines. Control T cells and serum were obtained from 31 healthy volunteers, similar in sex and age to the RA group. In the 2 months before sample collection, the patient had not used immunosuppressants and immunomodulators. All patients signed an informed consent form before sample collection. The research process complied with the research convention.

[0066] Synovial tissue...